Mr. Semerjian is a global biopharmaceutical veteran. Over the last 25 years, he acquired extensive US, European and international commercialization experience having led multiple successful hematology/oncology product launches, including preparation for the launch of midostaurin in AML.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at University of California (UC) Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit patients with treatment-naïve acute myeloid leukemia (AML). Brian A. Jonas, MD, PhD, FACP, UC Davis Division of Hematology/Oncology, is the clinical trial’s principal investigator.
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.
Mr. Hahn has more than 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as executive director of finance at Middlebrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly-traded specialty pharmaceutical company.
GlycoMimetics Appoints Dr. Myra Rosario Herrle as Vice President, Regulatory Affairs April 7, 2020 at 9:15 AM EDT PDF Version ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 7, 2020– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that [….]
